a study of safety and efficacy of kfa115 alone and in combo with pembrolizumab in patients with select advanced cancers

Conditions: Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms

Summary: the purpose of this study is to characterize the safety and tolerability of kfa115 and kfa115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

this is a phase i, open-label, multi-center study of kfa115 as a single agent and in combination with pembrolizumab. the study consists of a dose escalation part, followed by dose expansion part(s) for single-agent kfa115 and kfa115 in combination with pembrolizumab. the escalation parts will characterize safety and tolerability. after the determination of the maximum tolerated dose (mtd) / recommended dose (rd), the dose expansion parts will assess the preliminary anti-tumor activity in defined patient populations and further assess the safety and tolerability at mtd/rd.

Eligibility criteria:
inclusion criteria: * non-small cell lung cancer with historic pd-l1 ≥ 1%, as determined locally using a clinically accepted assay. patients must have experienced benefit from previous anti-pd(l)1-containing therapy for at least 4 months based on investigator-assessed disease stability or response prior to developing documented disease progression. patients must have also received prior platinum-based chemotherapy, either in combination or in sequence with anti-pd-(l)1, unless patient was ineligible to receive such treatment. * renal cell carcinoma, clear cell histology, previously treated with anti-pd(l)1-containing therapy and a vegf targeted therapy as monotherapy or in combination. patients should have documented disease progression following anti-pd(l)1-containing therapy. * cutaneous melanoma, previously treated with anti-pd(l)1-containing therapy. patients should have documented disease progression following anti-pd(l)1-containing therapy. patients with braf v600-mutant melanoma must have also received prior therapy with a braf v600 inhibitor, with or without a mek inhibitor. * ovarian cancer, high-grade serous histology, naïve to anti-pd(l)1 therapy, must have received one prior systemic therapy in platinum-resistant setting. * nasopharyngeal carcinoma, non-keratinizing locally advanced recurrent or metastatic. depending on the study arm, patients may be naïve to anti-pd(l)1 therapy, or previously treated with platinum-based chemotherapy with or without anti-pd-(l)1. * locally advanced unresectable or metastatic triple negative breast cancer, ovarian cancer (high-grade serous histology), anal cancer (squamous), msi-h crc, esophagogastric cancer, mesothelioma, and hnscc. * locally advanced unresectable or metastatic anal cancer (squamous), thymic carcinoma, msi-h crc, esophagogastric cancer, mesothelioma, and hnscc, all naïve to anti-pd(l)1 therapy and for whom anti pd(l)1 therapy is not available. * triple negative breast cancer with historic pd-l1 cps ≥ 1%, must have received at least one line of chemotherapy. in addition, these patients must have previously received sacituzumab govitecan, and in the case of a brca mutation a parp inhibitor, if these treatments are locally approved and accessible to the patient. exclusion criteria: * impaired cardiac function or clinically significant cardiac disease. * use of agents known to prolong the qt interval unless they can be permanently discontinued for the duration of study. * history of severe hypersensitivity reactions to any ingredient of study drug(s) and other mabs and/or their excipients. * active, known or suspected autoimmune disease. patients with vitiligo, type i diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur may be considered. patients previously exposed to anti-pd-1/pd-l1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded. * any evidence of interstitial lung disease (ild) or pneumonitis, or a prior history of ild or non-infectious pneumonitis requiring high-dose glucocorticoids. * patients who discontinued prior anti-pd-(l)1 therapy due to an anti-pd-(l)1-related toxicity (applicable to the kfa115 in combination with pembrolizumab treatment arms). * patients with symptomatic peripheral neuropathy limiting instrumental activities of daily living. other protocol-defined inclusion/exclusion criteria may apply

Keywords: lung cancer non-small-cell lung cancer nsclc malignant skin cancer skin cancer cutaneous melanoma renal cell carcinoma rcc kidney cancer renal cancer clear cell carcinoma cancer of the ovaries female reproductive cancer ovarian carcinoma epithelial ovarian cancer nasopharyngeal neoplasms nasopharyngeal carcinoma npc thymic carcinoma thymic tumor rectal cancer rectal neoplasms esophageal cancer cancer of throat colon cancer colorectal cancer bowel cancer cancer of the colon and rectum high microsatellite instability colorectal carcinoma crc msi-h crc advanced solid malignancies head and neck cancer hnscc scchn squamous cell carcinoma of the head and neck cancer advanced cancer nvp-kfa115 triple negative breast cancer tnbc mesothelioma anal cancer